| Literature DB >> 31089398 |
Cheng Chen1,2,3, Qi Zhao2, Yan Shao1, Yan Li1, Honghuan Song1, Guoli Li1, Limei Zhu1, Wei Lu1, Biao Xu2,3,4.
Abstract
BACKGROUND: ASAP1 (also known as AMAP1 or DDEF1) encodes an Arf GTPase-activating protein (Arf GAP), a multifunctional scaffold protein that induces hydrolysis of GTP bound to the ADP-ribosylation factor (Arf) family GTP-binding proteins. Reduction of ASAP1 expression in vitro was related to suppression of cell migration and invasiveness. The genetic variant rs4733781 of the ASAP1 gene was revealed as a significant locus for tuberculosis (TB) susceptibility, but the results still need to be validated.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31089398 PMCID: PMC6476032 DOI: 10.1155/2019/7945429
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Basic characteristics of participants free of TB infection, with LTBI, and of active TB for the ASAP1 expression assay.
| Participants | Sample numbers | Ages | Gender | Clinical diagnosis |
|---|---|---|---|---|
| Noninfected HC | 16 | 36 ± 5.94 (29~49) | Male: 3 | X-Ray negative, no symptoms of TB, and no other infectious diseases and history of TB reported |
| Female: 13 | ||||
| Latent TB-infected HC | 16 | 40.75 ± 7.34 (30~56) | Male: 2 | X-Ray negative, no symptoms of TB, and no other infectious diseases and history of TB reported |
| Female: 14 | ||||
| Active TB | 16 | 41.88 ± 20.60 (16~82) | Male: 10 | Culture confirmed, all with clinical symptoms and X-ray abnormality of TB |
| Female: 6 |
HC: healthy controls; TB: tuberculosis.
The genotype distribution of rs4733781 among tuberculosis cases and controls.
| SNP rs4733781 | Cases | Controls | ∗OR (95% CI) |
| IGRA-positive controls | ∗OR (95% CI) |
| IGRA-negative controls | ∗OR (95% CI) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| 954 | 951 | 215 | 736 | |||||||
| CC | 361 (37.8) | 304 (32.0) | 1.00 (reference) | 78 (36.3) | 1.00 (reference) | 226 (30.7) | 1.00 (reference) | |||
| CA | 461 (48.3) | 483 (50.8) | 0.81 (0.66-0.99) | 0.0373 | 102 (47.4) | 0.98 (0.71-1.35) | 0.8881 | 381 (51.8) | 0.76 (0.61-0.95) | 0.0159 |
| AA | 132 (13.8) | 164 (17.2) | 0.68 (0.51-0.89) | 0.0059 | 35 (16.2) | 0.82 (0.52-1.28) | 0.382 | 129 (17.5) | 0.64 (0.47-0.89) | 0.0034 |
| CA+AA | 593 (62.2) | 647 (68.0) | 0.78 (0.64-0.94) | 0.0086 | 137 (63.7) | 0.94 (0.69-1.28) | 0.677 | 510 (69.3) | 0.73 (0.60-0.90) | 0.0033 |
| MAF | 0.38 | 0.43 | ||||||||
| HWE | 0.24 |
∗Adjusted by age and gender. HWE: Hardy-Weinberg equilibrium; IGRA: interferon-gamma release assay.
Comparison of rs4733781 genotype distributions among IGRA-positive and IGRA-negative controls.
| SNP rs4733781 | IGRA-negative controls | IGRA-positive controls | ∗OR (95% CI) |
|
|---|---|---|---|---|
| 736 | 215 | |||
| CC | 226 (30.7) | 78 (36.3) | 1.00 (reference) | |
| CA | 381 (51.8) | 102 (47.4) | 0.75 (0.53-1.06) | 0.1007 |
| AA | 129 (17.5) | 35 (16.3) | 0.82 (0.51-1.31) | 0.3939 |
| CA+AA | 510 (69.3) | 137 (63.7) | 0.76 (0.55-1.06) | 0.1082 |
Figure 1ASAP1 expression difference among HC, LTBI, and TB. GSE19491 platform: Illumina HumanHT-12 V3.0 expression beadchip. GSE37250 platform: Illumina HumanHT-12 V4.0 expression beadchip. GSE42834 platform: Illumina HumanHT-12 V4.0 expression beadchip.